Correction: Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Publishing Group.
Chicago Style (17th ed.) CitationCorrection: Tofacitinib for the Treatment of Moderately to Severely Active Ulcerative Colitis: A Systematic Review, Network Meta-analysis and Economic Evaluation. BMJ Publishing Group.
MLA (9th ed.) CitationCorrection: Tofacitinib for the Treatment of Moderately to Severely Active Ulcerative Colitis: A Systematic Review, Network Meta-analysis and Economic Evaluation. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.